First Albany Raises Idec Estimates

Analyst David Webber sees stronger earnings growth for the drug maker on increased sales of Rituxan

First Albany raised its estimates on Idec Pharmaceutical (IDPH ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.